Susoctocog alfa 500unit powder and solvent for solution for injection vials
Requires a prescription from a doctor or prescriber
Intravenous susoctocog alfa is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Susoctocog alfa
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Susoctocog alfa
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Susoctocog alfa
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Susoctocog alfa on the MHRA register
Obizur 500unit powder and solvent for solution for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Trials: 1 · 2016–2026
Showing the 50 most relevant studies, sorted by most relevant.
Carola Sella, Marco Bardetta, Federica Valeri, et al.
Journal of Clinical Medicine, 2023
Background: Acquired hemophilia A (AHA) is a rare bleeding disease due to autoantibodies directed against clotting factor VIII (FVIII). Treatment of AHA consists of inhibitor eradication with immunosuppressive therapy (IST) and prompt control of bleeding obtained with bypassing agents or recombinant porcine FVIII (rpFVIII). The latter has recently been licensed for management of acute bleeding in AHA. Unlike treatment with bypassing agents, rpFVIII can be monitored to provide a successful hemostatic effect and avoid overtreatment. Correlation between rpFVIII inhibitor titers and efficacy of rpFVIII treatment remains a matter of debate. Methods: We report three cases of AHA in which rpFVIII was successfully used with an unconventional schedule despite the presence of medium–high titers of the rpFVIII. The modified Nijmegen–Bethesda inhibitor assay (NBA) was used to dose porcine FVIII inhibitors. Result: The presence of rpFVIII inhibitors prior to the exposition to susoctocog-alfa, that may suggest a cross-reactivity with human FVIII inhibitors, did not affect hemostasis. Conclusion: In our experience, rpFVIII demonstrates safety and efficacy in the presence of rpFVIII inhibitors and using an unconventional schedule in both the perioperative and outpatient settings. Laboratory measurement of inhibitors against rpFVIII during treatment is described for the first time.
Abstract licence: CC BY 4.0
Jerzy Windyga, Anna Buczma, Joanna Rupa-Matysek, et al.
Acta Haematologica Polonica, 2025
Celeste B. Burness, Lesley J. Scott
Drugs, 2016
- Antibodies
- Clinical Trials as Topic
- Factor VIII
Celeste B. Burness, Lesley J. Scott
Drugs, 2016
Sümeyra SOYSAL
Ahmet Keleşoğlu Eğitim Fakültesi Dergisi, 2023
Bu çalışmada çok boyutlu ölçümlerde iç tutarlık anlamında güvenirliğin değerlendirilmesinde Cronbach alfa katsayısı yerine daha uygun alternatiflerini kullanma konusunda farkındalık oluşmasına katkı sağlamak amaçlanmıştır. Bu amaç kapsamında örneklem büyüklüğü (100, 200 ve 400), boyutlar arası korelasyon (0,00 ve 0,50), maddeler arası korelasyon (0,30-0,50 ve ≥0,75), test uzunluğu (10 ve 20) ve boyutlara düşen madde sayısı (5-5, 7-3, 10-10 ve 15-5) koşulları altında iki boyutlu basit ve karmaşık test yapılarında üretilen verilerde alfa, tabakalı alfa ve omega katsayılarının performansı incelenmiştir. Ayrıca araştırmacılara tabakalı alfa ve omega katsayılarının manuel olarak kolaylıkla hesaplanabildiğini göstermek amacıyla örnekler sunulmuştur. Veriler R programı ile psych ve sirt paketleri kullanılarak analiz edilmiştir. Araştırmanın sonucunda güvenirlik kestirimleri üzerinde en fazla etkisi olan değişkenlerin sırasıyla maddeler arası korelasyon ve boyutlar arası korelasyon olduğu bulunmuştur. Test uzunluğunun ilişkisiz modellerde maddeler arası düşük korelasyon koşulu altında güvenirlik kestirimleri üzerinde daha fazla etkiye sahip olduğu görülmüştür. Örneklem büyüklüğü ortalama güvenirlik kestirimleri üzerinde etkili bulunmamıştır ancak kestirimlerin hatası üzerinde etkili bulunmuştur. Omega ve tabakalı alfa katsayılarının performansı benzer bulunurken alfa katsayısı ise bu katsayılardan daha düşük güvenirlik değerleri kestirmiştir. Hem alanyazına hem de mevcut çalışmanın sonuçlarına dayalı olarak araştırmacılara, çok boyutlu ölçümlerde iç tutarlılık anlamında güvenirlik kanıtı olarak alfa katsayısını kullanmamaları ya da tek başına kullanmamaları; bunun yerine omega, tabakalı alfa gibi daha uygun katsayıları kullanıp raporlamaları önerilir.
Abstract licence: CC BY-NC
Susan Guy, Annette E. Bowyer, M. Fiona Shepherd, et al.
International Journal of Laboratory Hematology, 2023
- Hemophilia A
- Hemostatics
- Actins
Fernández-Oliveira C, Rotea-Salvo S, Fernández-Docampo M, et al.
2023
- Cross Infection
- Hemophilia A
- COVID-19
Ayano Kihara, Masanori Tamaki, Ryohei Sumitani, et al.
CEN Case Reports, 2025
- Factor VIII
- Renal Dialysis
- Hemophilia A
Inga Schimansky, Christiane Dobbelstein, Andreas Tiede
Blood, 2025
Eiichiro Nagatani, Takeshi Hagino, Tomohiko Sato, et al.
Annals of Blood, 2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
2-17 hours
Mechanism
Factor VIII circulates in the plasma as a hemostatically active protein complex…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
26 minutes
Half-life
2-17 hours
Protein binding
Volume of distribution
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
In a global, prospective, controlled, multi-center Phase 2/3 open-label clinical trial, all patients responded to susoctocog alfa treatment within 24 hours [L1129]. Susoctocog alfa is a glycoprotein containing a 90 kDa heavy chain and a 80 kDa light chain with the naturally-occuring B domain replaced with a twenty-four amino acid linker.
Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection. It is the first recombinant porcine FVIII treatment approved for AHA that allows physicians to manage the treatment's efficacy and safety by measuring factor VIII activity levels in addition to clinical assessments [L1129]. The recombinant porcine sequence allows less susceptibility to inactivation by circulating human factor VIII antibodies.
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 92 interactions
[L1130]
Acquired haemophilia is a rare bleeding disorder where patients with normal Factor VIII genes spontaneously develop inhibitory autoantibodies directed against Factor VIII. These autoantibodies are IgG1 and IgG4 autoantibodies that bind to the A2, A3 and C2 domains of the FVIII molecules to inactivate them [A18443]. The autoantibodies neutralize circulating human factor VIII and create a functional deficiency of this procoagulant protein. Susoctocog alfa serves to temporarily restore the inhibited endogenous Factor VIII for effective hemostasis. Circulating inhibitory autoantibodies have minimal or no cross-reactivity against susoctocog alfa [FDA Label].
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L1130]
[L1130]
[L1130]
Proteins and enzymes this drug interacts with in the body
ATC B02BD14
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Susoctocog alfa
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72